Go Deep
Mankind Pharma Limited
Mankind Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,363 | 46.2 | 5.79 | 0.38 | 2,285.50 |
Mankind Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 40,305,900,000.0 | 34,429,300,000.0 | 35,672,000,000.0 | 35,703,500,000.0 |
| Net Profit | 5,680,600,000.0 | 5,543,500,000.0 | 4,087,500,000.0 | 4,383,200,000.0 |
| EPS | 13.8 | 13.4 | 9.9 | 10.6 |
Mankind Pharma Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 142,776,400,000.0 | 122,074,400,000.0 | 102,592,900,000.0 | 87,494,330,000.0 |
| Net Profit | 19,129,300,000.0 | 19,909,600,000.0 | 19,129,000,000.0 | 12,818,591,000.0 |
| EPS | 46.4 | 49.3 | 47.8 | 32.0 |
Mankind Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 280,795,300,000.0 | 277,595,300,000.0 | 119,632,500,000.0 | 97,154,491,000.0 | — |
| Total Liabilities | 115,184,800,000.0 | 131,913,500,000.0 | 23,874,600,000.0 | 20,921,562,000.0 | — |
| Total Equity | 163,003,400,000.0 | 143,323,900,000.0 | 93,630,900,000.0 | 74,352,228,000.0 | — |
Owes vs Owns
Mankind Pharma Limited owed ₹0.41 for every ₹1 it owned in Mar 2026, up from ₹0.22 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.41× | 0.48× | 0.20× | 0.22× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Mankind Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 7.8%Receivables 6.2%Inventory 7.6%Fixed assets (tangible) 13.2%Intangible assets 57.5%Long-term investments 0.7%Other assets 7.0%
How it's funded — Mar 2026
Short-term debt 12.0%Long-term debt 10.0%Payables 4.8%Other liabilities 14.1%Shareholders' equity 59.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,195.8 | 2,485.1 | 3,386.5 | 1,521.6 |
| Receivables | 1,729.5 | 1,538.3 | 848.3 | 576.4 |
| Inventory | 2,144.5 | 2,093.7 | 1,553.5 | 1,498.5 |
| Fixed assets (tangible) | 3,713.9 | 3,259.2 | 3,170.9 | 3,075.8 |
| Intangible assets | 16,133.7 | 16,616.2 | 1,683.1 | 1,778.4 |
| Long-term investments | 199.8 | 190.9 | 189.3 | 181.4 |
| Other assets | 1,962.2 | 1,576.1 | 1,131.7 | 1,083.3 |
| Liabilities & equity | ||||
| Short-term debt | 3,383.1 | 2,956.8 | 171.2 | 139.5 |
| Long-term debt | 2,821.2 | 5,526.2 | 24.9 | 23.1 |
| Payables | 1,341.3 | 1,133.4 | 777.1 | 1,008.2 |
| Other liabilities | 3,972.8 | 3,574.9 | 1,414.4 | 921.3 |
| Shareholders' equity | 16,561.0 | 14,568.2 | 9,575.8 | 7,623.3 |
| Net tangible assets | 166.6 | -2,283.8 | 7,680.0 | 5,656.8 |
Mankind Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 31,212,900,000.0 | 24,133,800,000.0 | 21,524,400,000.0 | 18,133,017,000.0 | — |
| Investing Activities | -1,964,200,000.0 | -126,829,500,000.0 | -20,816,900,000.0 | -10,541,287,000.0 | — |
| Financing Activities | -29,526,900,000.0 | 102,325,600,000.0 | 52,700,000.0 | -7,397,281,000.0 | — |